



16⁰⁰ 0350

PATENT

#12/B
10/30/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

Ariel Fletcher

Ariel Fletcher

10/15/2002
Date of Deposit

Applicant: Padidam, et al.)	
)	Group Art Unit: 1638
Serial No.: 09/622,500)	
)	Examiner: G. Helmer
Filed: August 17, 2000)	
)	
Title: RESISTANCE IN PLANTS TO)	Our Ref.: TSRI 615.1
INFECTION BY ssDNA VIRUS USING)	
INOVIIRIDAE VIRUS ssDNA-BINDING)	
PROTEIN, COMPOSITIONS AND)	
METHODS OF USE)	

TECH CENTER 1600/2900

RECEIVED
OCT 30 2002

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)

Assistant Commissioner for Patents
Attn: Box Sequence
P.O. Box 2327
Arlington, VA 22202

Dear Sirs:

In response to the enclosed copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed September 24, 2002, enclosed is a substitute Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the substitute Sequence Listing in computer readable form, submitted as required by 37 CFR

§1.821(e), on which the Sequence Listing is labeled TSRI 615.1.

Applicants respectfully request entry of the substitute Sequence Listing and computer readable copy thereof.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Entry of the following amendment is respectfully requested.

Please amend the above-identified application as follows:

In The Specification:

At page 26, line 16, please substitute the following paragraph for the previous version:

B¹
CP66:Stag:6G:g5

Similar to CP66:6G:g5 except that a sequence coding for the 15 aa Stag peptide epitope [KETAAAKFERQHMDs (SEQ ID NO:7); (Kim et al, J.S.,

B¹
con'd

Protein Sci., 2:348-356, 1993)] was inserted after Arg66 codon of CP. Stag epitope was inserted to immunolocalize the CP66:6G:g5 protein in protoplasts using the S-protein coupled to the FITC.

(At page 26, line 26, please substitute the following paragraph for the previous version:)

FCP66:6G:g5 A sequence coding for 9 aa Flag peptide epitope [MDYKDDDDK (SEQ ID NO:8); (Hopp et al, J. Immunol. Methods., 88:1-18, 1986)] was added before the Met1 codon of CP66:6G:g5 and cloned between Afl III (nt 125) and Sph I (nt 836). AV2 ORF is deleted in this construct. Flag epitope was added to immunoprecipitate the CP66:6G:g5 protein from protoplasts using the anti-Flag antibody.

At page 28, line 12, please substitute the following paragraph for the previous version:

B²

TBC1AV2-CP- Similar to BC1AV2-CP- except that sequence coding for 11 aa T7 [MASMTGGQMG (SEQ ID NO:9); (Krek et al, Cell, 78:161-172, 1994)] epitope was added before the Met1 codon of BC1. T7 tag epitope was added to immunolocalize the BC1 protein in protoplasts using the anti-T7 tag antibody.

Attached hereto is Appendix A which is a marked-up version of the changes made to the specification by the current amendment.

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

RECEIVED

OCT 30 2002

Applicant Must Provide:

TECH CENTER 1600/2900

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE